Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant respiratory syncytial virus vaccine (CHO cell)
- Development stage
- Unknown
- Lead developer
- Ab&B Bio-tech Co., Ltd.
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Recombinant respiratory syncytial virus vaccine (CHO cell) is a protein subunit vaccine candidate produced using Chinese Hamster Ovary (CHO) cell expression systems. It is designed to prevent respiratory syncytial virus (RSV) infection and associated lower respiratory tract disease (LRTD), particularly in older adults and other high-risk populations. The vaccine typically utilizes a recombinant version of the RSV fusion (F) protein, which is the primary target for neutralizing antibodies. Clinical development in China is being pursued by multiple entities, including Ab&B Bio-Tech (怡道生物科技) and Beijing Jinuo Sanitation Biotechnology (北京吉诺卫), with trials evaluating safety, tolerability, and immunogenicity, often in combination with various adjuvant systems to enhance the immune response.
- Other names
- 重组呼吸道合胞病毒疫苗（CHO细胞）Recombinant RSV Vaccine (CHO Cell)
02
Targets
RSV F (Respiratory syncytial virus fusion protein)
Beyond the preview
Go deeper on recombinant respiratory syncytial virus vaccine (CHO cell).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant respiratory syncytial virus vaccine (CHO cell).